10-Q: Health Catalyst Reports Wider Loss Amid Goodwill Impairment

Health Catalyst, Inc. reported a significantly wider net loss in Q2 2025, primarily driven by a substantial goodwill impairment charge, despite modest revenue growth.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 6% to $80.7 million, up from $75.9 million in the prior year period.
• Technology revenue grew 11% to $52.9 million, while professional services revenue slightly decreased by 1% to $27.8 million.
• Net loss for the three months ended June 30, 2025, widened significantly to $41.0 million, compared to a net loss of $13.5 million in the same period last year.
• The increased net loss was largely due to a non-cash goodwill impairment charge of $28.8 million.
• Adjusted EBITDA improved to $9.3 million for the three months ended June 30, 2025, up from $7.5 million in the prior year.
• Cash and cash equivalents decreased substantially from $249.6 million at December 31, 2024, to $50.7 million at June 30, 2025.
• Short-term investments also saw a significant reduction from $142.4 million to $46.6 million over the same period.
• Net cash used in operating activities for the six months ended June 30, 2025, was $8.7 million, a shift from $11.9 million provided in the prior year period.
• The company fully repaid its $230.0 million 2.50% Convertible Senior Notes due 2025 in cash on April 14, 2025.
• A new Credit Agreement was entered into on July 16, 2024, providing a five-year term loan facility of up to $225.0 million, with $162.7 million drawn as of June 30, 2025.
• The company repurchased 1,103,601 shares of common stock for $5.0 million during the six months ended June 30, 2025, with $24.8 million remaining under the share repurchase plan.
• The company completed the January 2025 Restructuring Plan, incurring $3.9 million in costs, and authorized an August 2025 Restructuring Plan to reduce the global workforce by approximately 9%.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significantly widened net loss driven by a large goodwill impairment, substantial cash burn, and a shift to negative operating cash flow. While Adjusted EBITDA improved and revenue grew modestly, the explicit mention of macroeconomic headwinds, elongated sales cycles, and anticipated lower client spend due to funding cuts paints a challenging near-term picture. The need for potential future capital raises also adds to the negative sentiment.

Positives

• Total revenue increased by 6% year-over-year for both the three and six months ended June 30, 2025, indicating continued top-line growth.
• Technology revenue, the higher-margin segment, showed strong growth of 11% for the quarter and 10% for the six-month period, driven by new and acquired clients, contractual escalators, and expanded support services.
• Adjusted EBITDA improved to $9.3 million for the quarter and $15.6 million for the six-month period, reflecting progress in cost reduction initiatives and operational efficiency.
• The company successfully repaid its $230.0 million Convertible Senior Notes due 2025 in cash, demonstrating effective debt management.
• The company is actively pursuing strategic cost optimization through restructuring plans, which are expected to reduce future operating expenses.

Negatives

• Net loss significantly widened to $41.0 million for the quarter and $64.7 million for the six-month period, primarily due to a $28.8 million non-cash goodwill impairment charge.
• Cash and cash equivalents decreased sharply from $249.6 million to $50.7 million, and short-term investments also declined significantly, indicating substantial cash burn.
• Operating activities shifted from providing $11.9 million in cash to using $8.7 million in cash for the six months ended June 30, 2025.
• Professional services revenue slightly decreased by 1% for the quarter and 0.4% for the six-month period, attributed to lower utilization rates and timing of one-time revenue items.
• Adjusted Technology Gross Margin decreased from 67% to 66% for the quarter and 68% to 67% for the six-month period, due to costs associated with transitioning clients to Azure and migrating to Health Catalyst Ignite.
• Adjusted Professional Services Gross Margin decreased from 20% to 18% for the quarter and 21% to 17% for the six-month period, impacted by lower utilization rates and increased costs related to pilot ambulatory operations.
• Interest and other (expense) income, net, shifted from income to a significant expense, primarily due to increased interest expense from the new credit agreement and decreased interest income on investments.
• The company identified indicators of goodwill impairment, including overall declines in stock price and market capitalization, and a downward revision of future revenue forecasts.

Risks

• Operating in a highly competitive industry with rapidly changing technologies and evolving regulatory requirements.
• Inability to successfully execute growth initiatives, business strategies, or cost reduction and restructuring initiatives, including the migration of existing clients to Health Catalyst Ignite.
• Macroeconomic challenges, including high inflation, high interest rates, uncertainty with tariffs, and cuts in Medicaid and research funding, which could prolong sales cycles and negatively impact bookings and revenue.
• Potential client dissatisfaction with the cloud-based data platform, software analytics applications, and expertise.
• Risk of existing clients not renewing contracts, renewing at lower fee levels, or declining to purchase additional technology and services.
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity could lead to data loss, litigation, and reputational damage.
• Dependence on third-party data sourcing, with risks of third parties blocking access or increasing fees.
• Fluctuations in results of operations, making quarter-to-quarter comparisons unreliable and potentially leading to stock price declines if expectations are not met.
• The term loan facility exposes the company to interest rate risks and contains restrictive covenants that may limit operational and growth flexibility.
• Changes in pricing strategy could affect results of operations and ability to attract or retain clients.
• Solution failure to provide accurate and timely information, or association with faulty clinical decisions or treatment, could lead to litigation and liability.
• Reliance on third-party providers like Microsoft Azure for computing infrastructure, with risks of disruption or increased costs.
• Failure by clients to obtain proper permissions and waivers for data use, potentially leading to claims or limiting data utilization.
• Increasing reliance on AI and machine learning technologies may expose the company to significant risks, including development challenges, regulatory uncertainties, and potential third-party claims.
• Future litigation could be costly and time-consuming, diverting management attention and resources.
• Significant portion of revenue derived from a limited number of largest clients, making the company vulnerable to contract loss or renegotiation.
• Long and unpredictable sales cycles, requiring considerable investment without guaranteed success.
• Inability to implement and maintain effective internal controls over financial reporting.
• Difficulties in integrating acquired companies or technologies, potentially diverting management attention and resulting in dilution or unforeseen liabilities.
• Intense competition for highly skilled employees, potentially impacting ability to attract and retain talent.
• Dependence on senior management team, with risks associated with loss of key personnel.
• Challenges in maintaining corporate culture amidst rapid growth and organizational change.
• Inability to grow at historical rates or meet market opportunity estimates.
• Risks associated with the use of open-source software and third-party licensed software.
• Failure to protect intellectual property rights or being sued for alleged infringement.
• Compliance with complex and evolving healthcare and data privacy/security laws (HIPAA, GDPR, CCPA, AI regulations).
• Arrangements with clinicians potentially constituting improper rendering of professional medical services or fee splitting under state laws.
• Potential for FDA to modify enforcement policies, subjecting software products to extensive regulatory requirements.
• Uncertain healthcare regulatory and political framework, including potential impacts from the One Big Beautiful Bill Act (OBBBA) on Medicaid funding.
• Taxing authorities asserting additional sales and use, value-added, or similar transactional taxes.
• Unanticipated changes in effective tax rate and additional tax liabilities, including from international operations or new tax rules.
• Limitations on the ability to use net operating losses (NOLs) to offset future taxable income.
• Comprehensive tax reform legislation, such as the Tax Cuts and Jobs Act of 2017 and the CARES Act, could adversely affect the business.
• Indebtedness could adversely affect financial condition and prevent fulfillment of debt obligations.
• Restrictive covenants in the Credit Agreement limiting ability to take certain actions.
• Exposure to interest rate risks with regard to the Term Loan Facility.
• Limited operating history in an evolving industry, making future prospects difficult to evaluate.
• Expectation to incur losses in the future and potential inability to generate sufficient revenue to achieve and maintain profitability.
• Volatility in the market price of common stock, potentially leading to loss of investment.
• Reliance on management's broad discretion in the use of proceeds from offerings, which may not produce a positive return.
• Dilution to stockholders from issuance of additional capital stock.
• Requirements of being a public company straining resources and diverting management attention.
• Limited experience of senior management team in managing a publicly-traded company.
• No intention to pay dividends on common stock, making return on investment dependent on stock price appreciation.
• Potential for securities class action litigation.
• Provisions in charter documents and Delaware law making acquisition more difficult.
• Exclusive forum provision limiting stockholders' ability to obtain a favorable judicial forum for disputes.
• Changes in accounting principles causing unanticipated fluctuations in financial results.

Future Outlook

The company anticipates continued negative impacts from macroeconomic challenges, including high inflation, high interest rates, tariffs, and cuts in Medicaid and research funding, which are expected to prolong sales cycles and negatively affect bookings and revenue in the second half of 2025. An increasing number of clients are opting for price reductions as part of the migration to Health Catalyst Ignite, resulting in lower overall spend. The company expects Adjusted Technology Gross Margin to fluctuate and potentially decline in the near term due to ongoing Ignite migration costs and Ninja Universe deployment costs. Total Adjusted Gross Margin is expected to fluctuate in the near term but improve over the long term due to a mix shift towards technology revenue. Annual Adjusted EBITDA is generally expected to continue to improve, though quarterly fluctuations may occur due to timing of non-recurring revenue and seasonality of operating costs. The August 2025 Restructuring Plan is expected to reduce the global workforce by approximately 9% in Q3 2025, primarily in R&D and sales and marketing, with at least $4.5 million in associated charges.

Management Comments

• "We were encouraged that, in general, the operating margins of our health system end market improved in 2024 and the first half of 2025 relative to 2022 and 2023."
• "However, the implications of any policy developments around Medicaid and research funding reductions, as well as implications of the evolving tariff landscape have had a negative impact on our business."
• "As a result, certain sales cycles have elongated and some opportunities, such as opportunities in Life Sciences, have pushed, which has negatively impacted our year-to-date bookings achievement and our expectations for revenue in the second half of 2025."
• "We have also seen that the aggregated average total ARR and non-recurring revenue for net new Platform Clients trended lower in the second quarter of 2025 compared to the first quarter of 2025 and was below the midpoint of the $300,000 to $700,000 aggregated average total ARR and non-recurring revenue range. We anticipate this trend may continue in the near term, primarily driven by the funding cuts previously mentioned."
• "We continue to proactively respond to the challenging macroeconomic environment with a strategic operating plan that emphasizes our offerings and go-to-market approach in the areas where we have the most competitive differentiation and where clients are most likely to achieve measurable financial and operational ROI both in the near term and over time."
• "Our Adjusted EBITDA improved year-over-year as a result of our revenue growth and cost reduction initiatives as well as the timing of some non-headcount expenses. We generally expect annual Adjusted EBITDA to continue to improve going forward, although it may fluctuate from quarter to quarter as a result of the timing of non-recurring revenue and the seasonality of certain operating costs."

Industry Context

The healthcare industry, particularly the health system end market, continues to face significant financial strain from macroeconomic challenges, including high inflation and rising interest rates. While operating margins for health systems showed some improvement in late 2024 and early 2025, recent policy developments like the One Big Beautiful Bill Act (OBBBA), which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years, are expected to create additional financial pressure. This environment is leading to elongated sales cycles and clients opting for cost savings, impacting bookings and revenue expectations for healthcare technology providers. The industry is also seeing a trend towards increased adoption of data and analytics solutions, but the pace of adoption and willingness to invest in new solutions are influenced by these financial pressures.

Comparison to Industry Standards

• The company's 6% revenue growth is modest compared to some high-growth SaaS or healthcare tech companies, but may be in line with or slightly above the average for established healthcare IT firms facing similar macroeconomic headwinds.
• The significant net loss driven by goodwill impairment is a specific company event, but goodwill impairments are not uncommon in industries undergoing rapid M&A and facing market valuation shifts, similar to other healthcare tech consolidators.
• The improvement in Adjusted EBITDA suggests operational efficiency gains, which is a positive indicator often sought by investors, especially when compared to peers struggling with profitability.
• The decline in cash and investments, coupled with negative operating cash flow, indicates a higher cash burn rate than typically desired for a healthy, growing tech company, potentially lagging behind more cash-generative industry leaders.
• The company's focus on a highly recurring revenue model (over 90% recurring) and contractual technology revenue escalators aligns with best practices for stability in the SaaS industry, providing a predictable revenue base that many competitors strive for.
• The challenges in professional services gross margin and client migration to Ignite with price reductions reflect common integration and adoption hurdles faced by companies undergoing significant platform transitions, similar to large-scale enterprise software migrations in other sectors.

Legal Proceedings

• The company is involved in legal proceedings from time to time that arise in the normal course of business, but management does not expect them to have a material adverse effect.
• No charges were recorded for legal proceedings during the three and six months ended June 30, 2025 and 2024.

Related Party Transactions

• Recognized revenue from Carle Health, a client with a member of its executive leadership team on the company's board of directors, of $4.5 million for Q2 2025 and $8.9 million for the six months ended June 30, 2025.
• Receivables from Carle Health were $0.1 million as of June 30, 2025, and deferred revenue was $1.0 million.
• Has revenue arrangements with clients that are also investors, none holding a significant amount of ownership.

Stakeholder Impact

• **Shareholders:** Significant net loss increase due to goodwill impairment and substantial cash burn could negatively impact share price and investment value. Share repurchase program may offer some support but is limited. Potential future dilution from capital raises is a risk.
• **Employees:** Recent and planned workforce reductions (January 2025 and August 2025 Restructuring Plans) will impact approximately 13% of the global workforce, leading to job losses and potential morale issues among remaining team members. Competition for skilled personnel remains intense.
• **Customers:** Macroeconomic challenges and Medicaid funding cuts may lead to clients seeking price reductions or elongating sales cycles, potentially impacting the value and scope of services received. Migration to Health Catalyst Ignite may offer enhanced functionality but also involves acclimation challenges.
• **Suppliers/Vendors:** Continued reliance on third-party cloud computing and hosting providers (e.g., Microsoft Azure) indicates ongoing business for these partners, but cost pressures could lead to renegotiations.
• **Creditors:** The repayment of convertible notes reduces one debt obligation, but the new term loan facility introduces floating interest rate risk and restrictive covenants, which could affect the company's ability to meet future obligations if financial performance deteriorates.

Next Steps

• Continue to monitor migrations from DOS to Health Catalyst Ignite platform.
• Proactively respond to the challenging macroeconomic environment with a strategic operating plan emphasizing competitive differentiation and measurable ROI.
• Continue investments in research and development, primarily enhancing Health Catalyst Ignite capabilities.
• Implement the August 2025 Restructuring Plan, reducing global workforce by approximately 9% during Q3 2025, with activities potentially continuing into Q4 2025 and 2026.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial results and reflect any required adjustments in Q3 2025 financial results.
• Continue to monitor the impact of inflationary pressures, market volatility, and other macroeconomic factors on estimates, including expected credit losses, goodwill impairment assessments, and fair value of assets.

Key Dates

Recommendation

The company faces significant headwinds, including a substantial goodwill impairment, negative operating cash flow, and explicit warnings about macroeconomic pressures impacting future bookings and revenue. However, it also demonstrates resilience with modest revenue growth, improved Adjusted EBITDA, and proactive cost-cutting measures through restructuring. The repayment of convertible notes strengthens the balance sheet by eliminating a near-term debt maturity. A seasoned investor would likely 'hold' to observe if the strategic operating plan, including the Health Catalyst Ignite migration and restructuring efforts, can effectively counter the external pressures and translate into sustained profitability and positive cash flow, rather than making a definitive 'buy' or 'sell' decision based on this mixed report.

Keywords

Healthcare Technology, Data Analytics, Cloud-based Platform, Patient Engagement, Professional Services, Health Catalyst Ignite, SEC Filing, 10-Q, Financial Results, Goodwill Impairment, Restructuring, Acquisitions, Debt Repayment, Healthcare IT, AI in Healthcare, Machine Learning, Healthcare Providers, Value-based Care, Corporate Governance, Risk Management